BioCentury
ARTICLE | Clinical News

FDA panel to discuss Avastin biosimilar from Amgen, Allergan

June 9, 2017 8:19 PM UTC

FDA’s Oncologic Drugs Advisory Committee (ODAC) will meet on July 13 to discuss a BLA for biosimilar ABP 215. Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) share rights to ABP 215, a proposed biosimilar for Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit, under a 2011 deal. The candidate's user fee action date is Sept. 14 (see BioCentury, Jan. 2, 2012 & Nov. 17, 2016)...

BCIQ Company Profiles

Allergan plc

Amgen Inc.